Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 18, 1999

View Archived Issues

Dusa updates Levulan PDT development

Endorex study shows immune response stimulation by ImmTher in human cancer cells

Immune Response reports data from phase I colon cancer vaccine study

Medco third quarter progress marked by initiation of phase II coronary diagnostic trial

Trega Biosciences and Novartis expand R&D collaboration

Antiviral advisory committee meets in early November to discuss NDA for anti-HIV drug

Alpha-glucosidase inhibition as a target for development of broad-based anti-hepatitis virus agents

Eisai allowed to market Alzheimer's drug in Japan

Ariad discloses a wide series of cellular signal transduction inhibitors

EPO receptor ligands unrelated to primary EPO structure patented by Chugai

Immunogenic compositions for the treatment or prevention of HPV infections from Cantab

Wyeth-Ayerst reports U.S. launch of immunosuppressant

Preclinical results indicate a new target for RP therapy: calcium channel blockade

American Cyanamid claims nonpeptide MMP/TACE inhibitors for wide range of indications

New treatments for schizophrenia in the pipeline at Merck

Inflazyme to commence phase Ib studies with new oral asthma therapy

RotaShield withdrawn from the market following reports of intussusception

Preclinical review of AR-R15896AR presented at recent symposium

Progress toward a universal flu vaccine?

Dopascan as a potential biomarker for Parkinson's disease; clinical results presented

KRP-297: a novel thiazolidinedione that improves impaired fatty acid oxidation

New treatment for GERD now available in U.S.

Neurocrine Biosciences' NBI-3001 granted fast track designation

Dura and Spiros initiate pivotal clinical program for Beclomethasone Spiros

Highlights from EASD annual meeting: DPP-IV inhibitor shows promise in type II diabetes

Lotronex NDA up for review next month by GI advisory committee

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...